SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary ...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene ...

And then there were two. Senti Bio, seeing the end of its cash runway hove into view, has pulled the plug on its liver cancer candidate and narrowed its focus onto two CAR-NK programs to preserve its ...

“These results show that inhibitory CARs have very interesting and underappreciated properties that can improve the performance of immune cell therapies,” said Wilson Wong, Ph.D., Professor of ...

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The ...

Senti Bio released a KOL segment discussing leukemia research and its lead program, SENTI-202, featuring Drs. Strickland and Rajangam. Senti Biosciences, Inc. has released a Virtual Investor KOL ...

Senti Biosciences (NASDAQ:SNTI) soared 29% on Tuesday after unveiling encouraging clinical data from its SENTI-202 cancer therapy program and securing Regenerative Medicine Advanced Therapy (RMAT) ...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and ...

Freshly equipped with a $105 million series B and a more than half-a-billion pact with Roche's gene therapy unit, Senti Biosciences is taking control of its manufacturing destiny. Bayer-backed Senti ...

Senti Biosciences, Inc. has announced that its CEO, Timothy Lu, participated in Nasdaq's Amplify Spotlight Series, where he discussed the company's proprietary Gene Circuit platform aimed at ...